In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Acceleron and Celgene develop bone loss candidate

Executive Summary

Acceleron Pharma (developing therapeutics that promote bone growth) and Celgene (cancer and inflammatory disease treatments) will together develop Acceleron's ACE011 bone-forming compound that is in Phase IIa clinical trials in cancer patients.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Intra-Biotech Deal
    • Co-Promotion
    • Includes Equity
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register